AstraZeneca's Farxiga Gets FDA OK to Reduce Hospitalization Risk in Type 2 Diabetes
21 Ottobre 2019 - 1:53PM
Dow Jones News
By Colin Kellaher
AstraZeneca PLC (AZN, AZN.LN) on Monday said the U.S. Food and
Drug Administration approved Farxiga to reduce the risk of
hospitalization for heart failure in adults with type 2
diabetes.
The U.K. drug maker said Farxiga is the first sodium-glucose
cotransporter 2 inhibitor approved in the U.S. to reduce the risk
of hospitalization for heart failure in type 2 diabetes patients
with established cardiovascular disease or multiple cardiovascular
risk factors.
The FDA nod follows an update to Farxiga's marketing
authorization in the EU in August. The drug is also under
regulatory review in China, with a decision anticipated in the
first half of 2020, AstraZeneca said.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 21, 2019 07:38 ET (11:38 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Apr 2023 a Apr 2024
